ProCE Banner Activity

Slides on Key Decisions in HIV Care: Polypharmacy and Cardiovascular Risk Considerations in Older PWH

Slideset Download
Learn key considerations for the use of ART in older PWH. Topics include current data and recommendations on polypharmacy, drug-drug interactions, drug-disease state interactions, and cardiovascular risk considerations

Released: November 29, 2021

Expiration: November 28, 2022

Share

Faculty

Jonathan Appelbaum

Jonathan Appelbaum, MD, FACP, AAHIVS

Laurie L. Dozier Jr, MD, Education Director
Professor of Internal Medicine
Florida State University College of Medicine
Tallahassee, Florida

Jens D. Lundgren

Jens D. Lundgren, MD, DMSc

Professor
Rigshospital, University of Copenhagen
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Jonathan Appelbaum, MD, FACP, AAHIVS

Laurie L. Dozier Jr, MD, Education Director
Professor of Internal Medicine
Florida State University College of Medicine
Tallahassee, Florida

Jonathan Appelbaum, MD, FACP, AAHIVS, has disclosed that he has received consulting fees from Merck and ViiV.

Jens D. Lundgren, MD, DMSc

Professor
Rigshospital, University of Copenhagen
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark